#USA #San Diego #Neurocrine #INGREZZA #Tardive Dyskinesia

Introduction

Neurocrine Biosciences, Inc. recently presented new, compelling data regarding the treatment of mild tardive dyskinesia (TD) with INGREZZA® (valbenazine) during the American Psychiatric Association's Annual Meeting. This new evidence emerges from a comprehensive clinician survey that provided significant insights into the functional impairments faced by patients and the efficacy of INGREZZA in improving their condition in a real-world context.

Understanding Tardive Dyskinesia

Tardive dyskinesia is a disorder resulting in uncontrolled, repetitive movements, often affecting the face, torso, and limbs. Symptoms can be both persistent and debilitating, potentially leading to severe disruptions in patients' lives. The condition frequently develops as a side effect of long-term treatment with certain antipsychotic medications prescribed for mental health disorders.

Key Findings from the Clinician Survey

According to the survey of 315 patients treated with INGREZZA, over 90% reported emotional, social, or physical impairments due to their mild TD symptoms before treatment. Notably, 96% of patients who initiated treatment with INGREZZA experienced improvements in their uncontrolled movements, with 86% reporting noticeable enhancements within just four weeks.

Dr. Sanjay Keswani, Chief Medical Officer of Neurocrine Biosciences, emphasized the significance of these results by stating, "Even mild tardive dyskinesia can profoundly affect a patient’s quality of life. Our findings underscore the importance of addressing these symptoms effectively to help patients regain their independence."

Improvements in Daily Functionality

Aside from managing involuntary movements, patients exhibited marked improvements across various functional metrics. The data revealed that nearly all patients with impacted functional status (96%) achieved better overall functionality post-treatment. Additionally, clinicians noted improvements in emotional health, social interactions, and essential daily activities such as eating and self-care.

For instance, in patients with disrupted speech (55), dexterity (54), or social interactions (77), improvements exceeded 90%. Among those who were employed or studying, 70% experienced increased capability to work or attend school after beginning therapy with INGREZZA.

Supporting Clinical Guidelines

The findings resonate well with the American Psychiatric Association's clinical guidelines, which advocate for considering treatment options like INGREZZA for patients suffering from mild TD, particularly when symptoms hinder their daily activities or affect patient preference for treatment. This survey and its encouraging outcomes add to the pre-existing body of evidence validating the efficacy of INGREZZA in managing TD symptoms.

Looking Ahead

The KINECT-PRO™ Phase 4 study highlighted howINGREZZA stands out as a once-daily treatment belonging to a selective vesicular monoamine transporter 2 (VMAT2) inhibitor class. It provides a swift therapeutic action without requiring dose titration, a significant advantage over many traditional treatments.

Going forward, as Neurocrine Biosciences continues to innovate and expand its research, the demand for further studies exploring the full potential of INGREZZA remains crucial. These advancements not only aim to validate current findings but also seek to enhance the lives of the estimated 800,000 adults in the U.S. coping with TD.

Conclusion

This newfound understanding of INGREZZA's impact on patients with mild tardive dyskinesia showcases the drug's potential to significantly enhance life quality. Through the combination of robust clinical evidence and patient testimonials, Neurocrine Biosciences is proving to be a formidable player in the fight against movement disorders, diligently working to relieve the burdens faced by those with tardive dyskinesia.